A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV.
Markets
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Logicbio Therapeutics (LOGC – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $6.10.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 78.0% and a 71.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
Logicbio Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.00.
Logicbio Therapeutics’ market cap is currently $184.8M and has a P/E ratio of -4.50. The company has a Price to Book ratio of 3.01.